Cord blood cells for low blood counts after immune therapy
Part of Blood & lymphatic clinical trials.
This trial tests if a single dose of umbilical cord blood cells can help patients whose blood counts stay dangerously low after CAR-T or antibody therapy. It aims to reduce the need for transfusions and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had CAR-T cell or dual antibody therapy and developed severe low blood counts (grade 3-4) that haven't improved with standard care for at least 3 weeks.
- Your neutrophils drop to grade 3 or higher within a week after stopping a blood-booster drug, or you still need frequent red blood cell or platelet transfusions.
- Your doctor expects you to live at least 6 more months.
- You are able to take care of yourself (ECOG score 0-2).
- You have not had or are not planning a stem cell transplant from your own body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
Hear when a new Refractory Immune Effector Cell-related Hemocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.